Alzenau, Germany

Karl Sch Onafinger

This inventor holds 1 USPTO granted patent. Top assignee: Cassella Aktiengesellschaft. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Karl Sch Onafinger

Introduction

Karl Sch Onafinger is a notable inventor based in Alzenau, Germany. He has made significant contributions to the field of chemistry, particularly through his innovative work with coumarin derivatives. His research focuses on addressing disorders related to elevated nitric oxide (NO) levels, showcasing his commitment to advancing medical science.

Latest Patents

Karl Sch Onafinger holds a patent for the "Use of coumarin derivatives." This invention relates to the application of coumarins of a specific general formula for controlling and preventing disorders that arise due to elevated NO levels. His patent represents a crucial step in developing therapeutic solutions for related health issues.

Career Highlights

Throughout his career, Karl has been associated with Cassella Aktiengesellschaft, a company known for its contributions to the chemical industry. His work has not only advanced the understanding of coumarin derivatives but has also paved the way for potential medical applications.

Collaborations

Karl has collaborated with several professionals in his field, including Peter Klemm and J Org Ostrowski, who is now deceased. These collaborations have enriched his research and contributed to the development of innovative solutions in chemistry.

Conclusion

Karl Sch Onafinger's work exemplifies the spirit of innovation in the field of chemistry. His contributions, particularly in the use of coumarin derivatives, highlight the importance of research in addressing health-related challenges. His legacy continues to inspire future advancements in medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…